Buradasınız

Anasayfa » Content

Targeted therapy against cytokines and chemokines in cancer

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2015
Author Name
Abstract (2. Language): 
Cytokines are a diverse group of non-antibody proteins that act as mediators between cells.They mediate & regulate amplitude and duration of immune & inflammatory responses.They are important specifically in host responses to infection, immune responses, inflammation, trauma, sepsis, cancer, and reproduction. The interaction between cytokines & chemokines and their receptors forms a network at tumour site responsible for tumour progression and induction of anti tumour responses and tumour rejection. These affect multiple pathways of tumour progression including leucocyte recruitment, cellular scenescence, tumour cell proliferation & survival, angiogenesis, invasion and metastasis. These also have role in cancer cachexia, act as anti tumour agents and as prognostic markers. Cytokine therapy is given to manipulate the immune response in such a way as to generate the appropriate immune effector cells to eradicate various solid tumors.There have been clinical trials executed involving the administration of interferon-gamma, interferon-alpha, interleukin-2, tumor necrosis factor-alpha, and Interleukin-12. Cytokine-based anticancer agents and antagonists to chemokines possess high potential for the development of therapeutic agents to treat various types of malignant cancer. Important ones are Aldesleukin, Sunitinib, Bevacizumab, Maraviroc and many more. Future applications of cytokine therapy may involve a combination of cytokines in the treatment of advanced malignancies. In particular, the combination of IL-2 and IL-12 may prove to be the most effective regimen.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-targeted-therapy-against-cytokines-and-chemokines-cancer.pdf
  • 2
465
475
  • English

REFERENCES

References: 

1. Federica Barbieri, Adriana Bajetto, and Tullio Florio. Role of Chemokine Network in the Development and
Progression of Ovarian Cancer: A Potential Novel Pharmacological Target. Journal of Oncology, vol. 2010,
Article ID 426956, 15 pages, 2010.
2. Shurin MR1, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL.
Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?
Cancer Metastasis Rev. 2006 Sep;25(3):333-56.
3. Glen Dranoff. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer 4, January
2004;11-22 .
4. Mantovani A. Cancer: inflaming metastasis. Nature 2009;457:36–7.
5. Mantovani A, et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2009.
6. Mitchell J. Frederick and Gary L. Clayman (2001). Chemokines in cancer. Expert Reviews in Molecular
Medicine, pp 1-18.
7. Sergei I. Grivennikov, Florian R. Greten, Michael Karin. Immunity, Inflammation and Cancer. Cell 2010
March 19 ;140(6): 883-899.
8. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545.
9. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135–
141.
10. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature
2001;410:50–6.
11. Lyle L. Moldawer, Michael A. Rogy and Stephen F. Lowry.The Role of Cytokines in Cancer Cachexia.
JPEN J Parenter Enteral Nutr 1992 vol 16 no.6 suppl 43S- 49S.
12. Li Y, Qiu X, Zhang S, Zhang Q, Wang E. Hypoxia induced CCR7 expression via HIF-1alpha and HIF-
2alpha correlates with migration and invasion in lung cancer cells. Cancer Biol Ther 2009;8:322–30.
13. A Ben- Baruch. Host microenvironment in breast cancer development: Inflammatory cells, cytokines and
chemokines in breast cancer progression: reciprocal tumor–microenvironment interactions. Breast Cancer Res.
2003; 5(1): 31–36.
14. R. S. Freedman, Q. Ma, E. Wang, et al. Migration deficit in monocyte-macrophages in human ovarian
cancer. Cancer Immunology, Immunotherapy, vol. 57, no. 5, 2008, 635–645.
15. Sylvia Lee and Kim Margolin. Cytokines in Cancer Immunotherapy. Cancers 2011, 3, 3856 – 3893.
16. Murphy WJ, Back TC, Conlon KC, Komschlies KL, Ortaldo JR, Sayers TJ, et al. Antitumor effects of
interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J Clin Invest. 1993; 92:1918–
1924.
474
Indian Journal of Basic and Applied Medical Research; March 2015: Vol.-4, Issue- 2, P. 465-475
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
466
17. Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the
management of cancer-related anorexia/cachexia. J Am Med Dir Assoc. 2011;12(1):62–67.
18. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in
non-small cell lung cancer. Expert Opin Biol Ther. 2011;11(12):1663-1668.
19. Prado CM, Bekaii-Saab T, Doyle LA, et al. Skeletal muscle anabolism is a side effect of therapy with the
MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012;106(10):1583–1586.
20. Giovanni Mantovani, Clelia Madeddu, Antonio Maccio. Drugs in development for treatment of patients with
cancer related anorexia and cachexia syndrome. Drug Des Devel Ther 2013;7: 645-646.
21. Mitsiades N, Poulaki V, Mitsiades C and Tsokos M. Ewing's sarcoma family tumors are sensitive to tumor
necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res
2001, 61, 2704-12.
22. C. A. Lamartiniere. Protection against breast cancer with genistein: a component of soy. American Journal of
Clinical Nutrition, vol. 71, supplement 6, 2000, 1705S–1709S.
23. Ken Garber. First Results for Agents Targeting Cancer- Related Inflammation. JNCI J Natl Cancer Inst 2009.
24. Kumar S, et al. A therapeutic perspective of cytok-ines in tumor management. Inflamm Cell Signal.2014 ; 1
: 134- 138.

Thank you for copying data from http://www.arastirmax.com